Clinical Trial Update: Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

View source ↗

Summary

This clinical trial update notes that a study of nedosiran for Primary Hyperoxaluria Type 1 is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• nedosiran (nedosiran)

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria Type 1 (PH1) | Status: NO_LONGER_AVAILABLE